S. X. Huang, M. C. Jaurand, D. W. Kamp, J. Whysner, and T. K. Hei, Role of mutagenicity in asbestos fiberinduced carcinogenicity and other diseases, J Toxicol Environ Health B Crit Rev, vol.14, pp.179-245, 2011.

A. Scherpereel, P. Astoul, P. Baas, T. Berghmans, H. Clayson et al., Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, Eur Respir J, vol.35, pp.479-95, 2010.

M. Musti, E. Kettunen, S. Dragonieri, P. Lindholm, D. Cavone et al., Cytogenetic and molecular genetic changes in malignant mesothelioma, Cancer Genet Cytogenet, vol.170, pp.9-15, 2006.

P. M. Lindholm, K. Salmenkivi, H. Vauhkonen, A. G. Nicholson, S. Anttila et al., Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH, Cytogenet Genome Res, vol.119, pp.46-52, 2007.

T. Taniguchi, S. Karnan, T. Fukui, T. Yokoyama, H. Tagawa et al., Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32, Cancer Sci, vol.98, pp.438-484, 2007.

D. Jean, J. Daubriac, L. Pimpec-barthes, F. Galateau-salle, F. et al., Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02478588

D. Jean, E. Thomas, M. E. Renier, A. De-reynies, A. Lecomte et al., Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.178, pp.881-94, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00531343

H. L. Kindler, T. G. Karrison, D. R. Gandara, C. Lu, L. M. Krug et al., doubleblind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma, J Clin Oncol, vol.30, pp.2509-2524, 2012.

P. Bertino, M. Carbone, and H. Pass, Chemotherapy of malignant pleural mesothelioma, Expert Opin Pharmacother, vol.10, pp.99-107, 2009.

P. G. Betta, C. Magnani, T. Bensi, N. F. Trincheri, and S. Orecchia, Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma, Arch Pathol Lab Med, vol.136, pp.253-61, 2012.

A. N. Husain, T. Colby, N. Ordonez, T. Krausz, R. Attanoos et al., Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, vol.137, pp.647-67, 2012.

Y. Goto, K. Shinjo, Y. Kondo, L. Shen, M. Toyota et al., Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma, Cancer Res, vol.69, pp.9073-82, 2009.

B. C. Christensen, E. A. Houseman, J. J. Godleski, C. J. Marsit, J. L. Longacker et al., Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome, Cancer Res, vol.69, pp.227-261, 2009.

G. J. Gordon, G. N. Rockwell, R. V. Jensen, J. G. Rheinwald, J. N. Glickman et al., Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using largescale transcriptional profiling, Am J Pathol, vol.166, pp.1827-1867, 2005.

M. Guled, L. Lahti, P. M. Lindholm, K. Salmenkivi, I. Bagwan et al., CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis, Genes Chromosomes Cancer, vol.48, pp.615-638, 2009.

Y. Xu, M. Zheng, R. E. Merritt, J. B. Shrager, H. Wakelee et al., microRNA-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma, Chest, 2013.

A. N. Husain, T. V. Colby, N. G. Ordonez, T. Krausz, A. Borczuk et al., Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, vol.133, pp.1317-1348, 2009.

L. Zeng, J. Fleury-feith, I. Monnet, C. Boutin, J. Bignon et al., Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies, Hum Pathol, vol.25, pp.227-261, 1994.

L. Zeng, A. Buard, I. Monnet, C. Boutin, J. Fleury et al., In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines, Int J Cancer, vol.55, pp.515-535, 1993.

M. Bott, M. Brevet, B. S. Taylor, S. Shimizu, T. Ito et al., The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, vol.43, pp.668-72, 2011.

P. Andujar, J. Wang, A. Descatha, F. Galateau-salle, I. Abd-alsamad et al., p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos, Lung Cancer, vol.67, pp.23-30, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00388198

P. Andujar, J. C. Pairon, A. Renier, A. Descatha, I. Hysi et al., Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma, Mutagenesis, vol.28, pp.323-354, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02478590

R. A. Irizarry, B. M. Bolstad, C. F. Cope, L. M. Hobbs, B. Speed et al., Summaries of Affymetrix GeneChip probe level data, Nucleic Acids Res, vol.31, p.15, 2003.

S. Cairo, C. Armengol, D. Reynies, A. Wei, Y. Thomas et al., Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer, Cancer Cell, vol.14, pp.471-84, 2008.

R. Tibshirani, T. Hastie, B. Narasimhan, and G. Chu, Diagnosis of multiple cancer types by shrunken centroids of gene expression, Proc Natl Acad Sci U S A, vol.99, pp.6567-72, 2002.

B. Efron and R. Tibshirani, Empirical bayes methods and false discovery rates for microarrays, Genet Epidemiol, vol.23, pp.70-86, 2002.

J. J. Goeman, S. A. Van-de-geer, F. De-kort, and H. C. Van-houwelingen, A global test for groups of genes: testing association with a clinical outcome, Bioinformatics, vol.20, pp.93-102, 2004.

I. Dinu, J. D. Potter, T. Mueller, Q. Liu, A. J. Adewale et al., Improving gene set analysis of microarray data by SAM-GS, BMC Bioinformatics, vol.8, p.242, 2007.

J. J. Goeman and P. Buhlmann, Analyzing gene expression data in terms of gene sets: methodological issues, Bioinformatics, vol.23, pp.980-987, 2007.

G. Levallet, M. Vaisse-lesteven, L. Stang, N. Ilg, A. G. Brochard et al., Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group, J Thorac Oncol, vol.7, pp.599-606, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01853402

J. Zavadil and E. P. Bottinger, TGF-beta and epithelial-to-mesenchymal transitions, Oncogene, vol.24, pp.5764-74, 2005.

J. P. Thiery and J. P. Sleeman, Complex networks orchestrate epithelial-mesenchymal transitions, Nat Rev Mol Cell Biol, vol.7, pp.131-173, 2006.

M. Zeisberg and E. G. Neilson, Biomarkers for epithelial-mesenchymal transitions, J Clin Invest, vol.119, pp.1429-1466, 2009.

J. H. Taube, J. I. Herschkowitz, K. Komurov, A. Y. Zhou, S. Gupta et al., Core epithelial-tomesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes, Proc Natl Acad Sci U S A, vol.107, pp.15449-54, 2010.

X. Dhalluin and A. Scherpereel, Treatment of malignant pleural mesothelioma: current status and future directions, Monaldi Arch Chest Dis, vol.73, pp.79-85, 2010.

L. Greillier, S. Marco, and F. Barlesi, Targeted therapies in malignant pleural mesothelioma: a review of clinical studies, Anticancer Drugs, vol.22, pp.199-205, 2011.

J. N. Jakobsen and J. B. Sorensen, Review on clinical trials of targeted treatments in malignant mesothelioma, Cancer Chemother Pharmacol, vol.68, pp.1-15, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00694874

C. D. Hoang, D. 'cunha, J. Kratzke, M. G. Casmey, C. E. Frizelle et al., Gene expression profiling identifies matriptase overexpression in malignant mesothelioma, Chest, vol.125, pp.1843-52, 2004.

F. Gueugnon, S. Leclercq, C. Blanquart, C. Sagan, L. Cellerin et al., Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am J Pathol, vol.178, pp.1033-1075, 2011.

F. Lopez-rios, S. Chuai, R. Flores, S. Shimizu, T. Ohno et al., Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction, Cancer Res, vol.66, pp.2970-2979, 2006.

M. Kanamori-katayama, A. Kaiho, Y. Ishizu, Y. Okamura-oho, O. Hino et al., LRRN4 and UPK3B are markers of primary mesothelial cells, PLoS One, vol.6, p.25391, 2011.

S. Idell, S. Pueblitz, S. Emri, Y. Gungen, L. Gray et al., Regulation of fibrin deposition by malignant mesothelioma, Am J Pathol, vol.147, pp.1318-1347, 1995.

S. E. Mutsaers, C. M. Prele, A. R. Brody, and S. Idell, Pathogenesis of pleural fibrosis, Respirology, vol.9, pp.428-468, 2004.

H. I. Pass, Z. Liu, A. Wali, R. Bueno, S. Land et al., Gene expression profiles predict survival and progression of pleural mesothelioma, Clin Cancer Res, vol.10, pp.849-59, 2004.

G. J. Gordon, R. V. Jensen, L. L. Hsiao, S. R. Gullans, J. E. Blumenstock et al., Using gene expression ratios to predict outcome among patients with mesothelioma, J Natl Cancer Inst, vol.95, pp.598-605, 2003.

G. J. Gordon, G. N. Rockwell, P. A. Godfrey, R. V. Jensen, J. N. Glickman et al., Validation of genomics-based prognostic tests in malignant pleural mesothelioma, Clin Cancer Res, vol.11, pp.4406-4420, 2005.

G. J. Gordon, L. Dong, B. Y. Yeap, W. G. Richards, J. N. Glickman et al., Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma, J Natl Cancer Inst, vol.101, pp.678-86, 2009.

J. R. Testa, M. Cheung, P. J. Below, J. E. Tan, Y. Sementino et al., Germline BAP1 mutations predispose to malignant mesothelioma, Nat Genet, vol.43, pp.1022-1027, 2011.

P. Kapur, S. Pena-llopis, C. A. Zhrebker, L. , P. et al., Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation, Lancet Oncol, vol.14, pp.159-67, 2013.

J. W. Harbour, M. D. Onken, E. D. Roberson, S. Duan, L. Cao et al., Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, vol.330, pp.1410-1413, 2010.

M. G. Zauderer, M. Bott, R. Mcmillan, C. S. Sima, V. Rusch et al., Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations, J Thorac Oncol, vol.8, pp.1430-1433, 2013.

A. S. Abutaily, B. J. Addis, and W. R. Roche, Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies, J Clin Pathol, vol.55, pp.662-670, 2002.

A. Fassina, R. Cappellesso, V. Guzzardo, D. Via, L. Piccolo et al., Epithelialmesenchymal transition in malignant mesothelioma, Mod Pathol, vol.25, pp.86-99, 2012.

H. Merikallio, P. Paakko, K. Salmenkivi, V. Kinnula, T. Harju et al., Expression of snail, twist, and Zeb1 in malignant mesothelioma, APMIS, vol.121, pp.1-10, 2013.

A. Schramm, I. Opitz, S. Thies, B. Seifert, H. Moch et al., Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma, Eur J Cardiothorac Surg, vol.37, pp.566-72, 2010.

M. K. Wendt, M. Tian, and W. P. Schiemann, Deconstructing the mechanisms and consequences of TGFbeta-induced EMT during cancer progression, Cell Tissue Res, vol.347, pp.85-101, 2012.

R. J. Akhurst and A. Hata, Targeting the TGFbeta signalling pathway in disease, Nat Rev Drug Discov, vol.11, pp.790-811, 2012.

S. Lamouille, D. Subramanyam, R. Blelloch, and R. Derynck, Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs, Curr Opin Cell Biol, vol.25, pp.200-207, 2013.

, The expression of EMT positive markers (POSTN, VCAN, SNAI2, TCF4, HMGA2) and negative markers (CDH1, CDH3) was measured by qRT-PCR, and differential expression of these markers between C1 and C2 samples was tested using Mann-Whitney tests in MPM in culture (upper panel) and in MPM tumor samples (lower panel). For each tested marker, box plots of -??Ct normalized values are shown for C1 (blue) and C2 (red), respectively. MPM and p-values are indicated above. Data showed up-regulation of EMT positive marker expression and down-regulation of negative marker, gives the log2 ratio of expression between C2 and C1 samples. (B)

, A-B) Cell extracts prepared from 25 different epithelioid MPM in culture were submitted to SDS-PAGE and analyzed by Western blot using anti-E-cadherin antibody. GAPDH expression was also analyzed in controls. Representative Western blots are shown (A). E-cadherin is detected as a protein of 120 kDa in all of the C1 MPM. Each band corresponding to E-cadherin and GAPDH was quantified, expressed using arbitrary units and normalized to the expression of MESO_07 cells. The ratio Ecadherin/GAPDH is shown on the graph for each MPM subgroup (B). E-cadherin expression at the protein level is higher in C1 than in C2 MPM in culture. (C-F) E-cadherin immunostaining of paraffinembedded tumors in representative cases of epithelioid (C,D) and biphasic (E,F) MPM is shown, MPM molecular subgroups